Clinical review of the Resolute® zotarolimus-eluting stent for the treatment of coronary artery disease. (February 2012)

• Record Type: Journal Article
• Authors: Vasaiwala, Samip; Mauri, Laura
• Is Part Of: Interventional cardiology. Volume 4:Number 1(2012)
• Page Start: 33
• Page End: 43
• Publication Date: 2012-02
• Subjects: drug-eluting stents -- restenosis -- zotarolimus-eluting stent; Cardiology -- Periodicals; Coronary heart disease -- Treatment -- Periodicals; 616.1205
• DOI: 10.2217/ica.11.85
• Languages: English
• ISSNs: 1755-5310

Abstract

Drug-eluting stents (DES) offer reduced rates of clinical and angiographic restenosis compared with bare-metal stents in patients with symptomatic coronary artery disease. Despite availability of multiple different DES, concerns remain regarding relative efficacy and long-term safety. A DES that has optimal efficacy that extends to higher risk cases – specifically to maintain low restenosis rates in patients with diabetes and in small vessels or long lesions – yet has minimal safety concerns is the goal. The Resolute ® zotarolimus-eluting stent (R-ZES) is a new generation DES currently approved for use in Europe and awaiting approval in the USA. The R-ZES utilizes a novel biocompatible polymer on a cobalt–chromium stent platform in order to prolong the duration of drug elution and improve efficacy. This review will summarize the clinical data for the R-ZES in detail and discuss results in the context of the current landscape for percutaneous coronary intervention.